Cargando…

Urodynamic outcomes after pelvic nerve-sparing radical hysterectomy with or without neoadjuvant chemotherapy

OBJECTIVE: Our purposes of this study were to characterize a group of bulky cervical cancer patients who underwent a nerve sparing radical hysterectomy (NSRH) with or without neoadjuvant chemotherapy (NAC), to compare surgical outcomes and the preservation of bladder function, and to compare prognos...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsunetoh, Satoshi, Terai, Yoshito, Takai, Masaaki, Fujiwara, Satoe, Tanaka, Yoshimichi, Tanaka, Tomohito, Sasaki, Hiroshi, Ibuki, Naokazu, Ubai, Takanobu, Yamamoto, Kazuhiro, Azuma, Haruhito, Ohmichi, Masahide
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6718266/
https://www.ncbi.nlm.nih.gov/pubmed/31497250
http://dx.doi.org/10.18632/oncotarget.27147
_version_ 1783447706334658560
author Tsunetoh, Satoshi
Terai, Yoshito
Takai, Masaaki
Fujiwara, Satoe
Tanaka, Yoshimichi
Tanaka, Tomohito
Sasaki, Hiroshi
Ibuki, Naokazu
Ubai, Takanobu
Yamamoto, Kazuhiro
Azuma, Haruhito
Ohmichi, Masahide
author_facet Tsunetoh, Satoshi
Terai, Yoshito
Takai, Masaaki
Fujiwara, Satoe
Tanaka, Yoshimichi
Tanaka, Tomohito
Sasaki, Hiroshi
Ibuki, Naokazu
Ubai, Takanobu
Yamamoto, Kazuhiro
Azuma, Haruhito
Ohmichi, Masahide
author_sort Tsunetoh, Satoshi
collection PubMed
description OBJECTIVE: Our purposes of this study were to characterize a group of bulky cervical cancer patients who underwent a nerve sparing radical hysterectomy (NSRH) with or without neoadjuvant chemotherapy (NAC), to compare surgical outcomes and the preservation of bladder function, and to compare prognoses. RESULTS: Fifty-three patients had NSRH without NAC (Group A), and 33 patients had NSRH after NAC (Group B). With regard to prognostic factors, there was only a significant difference between both groups with regard to lymph node metastasis (15% vs 42%, P = 0.01). Moreover, bladder function in Group B patients improved to the same extent as the preoperative rate three months postoperatively. These data were similar to the results in Group A. With regard to overall survival, the 5-year survival rate was 98.1% (95% confidence interval (CI) 87.8–99.7) in Group A and 86.7% (95% CI 71.7–96.7) in Group B (P > 0.1). METHODS: We retrospectively identified 86 patients with cervical cancer who underwent NSRH at Osaka Medical College from May 2009 to November 2016. NAC was performed via balloon occluded arterial infusion. We extracted data on the patient's stage of progress, tumor volume, histological subtype, bleeding volume, urodynamic study results, and postoperative complications. The data were divided into two groups - those patients who received NAC and those who did not - and then compared. CONCLUSIONS: According to our analysis, NSRH surgery after NAC via balloon occluded arterial infusion brings beneficial results to patients with bulky IB2 to IIB cervical cancers.
format Online
Article
Text
id pubmed-6718266
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-67182662019-09-06 Urodynamic outcomes after pelvic nerve-sparing radical hysterectomy with or without neoadjuvant chemotherapy Tsunetoh, Satoshi Terai, Yoshito Takai, Masaaki Fujiwara, Satoe Tanaka, Yoshimichi Tanaka, Tomohito Sasaki, Hiroshi Ibuki, Naokazu Ubai, Takanobu Yamamoto, Kazuhiro Azuma, Haruhito Ohmichi, Masahide Oncotarget Research Paper OBJECTIVE: Our purposes of this study were to characterize a group of bulky cervical cancer patients who underwent a nerve sparing radical hysterectomy (NSRH) with or without neoadjuvant chemotherapy (NAC), to compare surgical outcomes and the preservation of bladder function, and to compare prognoses. RESULTS: Fifty-three patients had NSRH without NAC (Group A), and 33 patients had NSRH after NAC (Group B). With regard to prognostic factors, there was only a significant difference between both groups with regard to lymph node metastasis (15% vs 42%, P = 0.01). Moreover, bladder function in Group B patients improved to the same extent as the preoperative rate three months postoperatively. These data were similar to the results in Group A. With regard to overall survival, the 5-year survival rate was 98.1% (95% confidence interval (CI) 87.8–99.7) in Group A and 86.7% (95% CI 71.7–96.7) in Group B (P > 0.1). METHODS: We retrospectively identified 86 patients with cervical cancer who underwent NSRH at Osaka Medical College from May 2009 to November 2016. NAC was performed via balloon occluded arterial infusion. We extracted data on the patient's stage of progress, tumor volume, histological subtype, bleeding volume, urodynamic study results, and postoperative complications. The data were divided into two groups - those patients who received NAC and those who did not - and then compared. CONCLUSIONS: According to our analysis, NSRH surgery after NAC via balloon occluded arterial infusion brings beneficial results to patients with bulky IB2 to IIB cervical cancers. Impact Journals LLC 2019-08-27 /pmc/articles/PMC6718266/ /pubmed/31497250 http://dx.doi.org/10.18632/oncotarget.27147 Text en Copyright: © 2019 Tsunetoh et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Tsunetoh, Satoshi
Terai, Yoshito
Takai, Masaaki
Fujiwara, Satoe
Tanaka, Yoshimichi
Tanaka, Tomohito
Sasaki, Hiroshi
Ibuki, Naokazu
Ubai, Takanobu
Yamamoto, Kazuhiro
Azuma, Haruhito
Ohmichi, Masahide
Urodynamic outcomes after pelvic nerve-sparing radical hysterectomy with or without neoadjuvant chemotherapy
title Urodynamic outcomes after pelvic nerve-sparing radical hysterectomy with or without neoadjuvant chemotherapy
title_full Urodynamic outcomes after pelvic nerve-sparing radical hysterectomy with or without neoadjuvant chemotherapy
title_fullStr Urodynamic outcomes after pelvic nerve-sparing radical hysterectomy with or without neoadjuvant chemotherapy
title_full_unstemmed Urodynamic outcomes after pelvic nerve-sparing radical hysterectomy with or without neoadjuvant chemotherapy
title_short Urodynamic outcomes after pelvic nerve-sparing radical hysterectomy with or without neoadjuvant chemotherapy
title_sort urodynamic outcomes after pelvic nerve-sparing radical hysterectomy with or without neoadjuvant chemotherapy
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6718266/
https://www.ncbi.nlm.nih.gov/pubmed/31497250
http://dx.doi.org/10.18632/oncotarget.27147
work_keys_str_mv AT tsunetohsatoshi urodynamicoutcomesafterpelvicnervesparingradicalhysterectomywithorwithoutneoadjuvantchemotherapy
AT teraiyoshito urodynamicoutcomesafterpelvicnervesparingradicalhysterectomywithorwithoutneoadjuvantchemotherapy
AT takaimasaaki urodynamicoutcomesafterpelvicnervesparingradicalhysterectomywithorwithoutneoadjuvantchemotherapy
AT fujiwarasatoe urodynamicoutcomesafterpelvicnervesparingradicalhysterectomywithorwithoutneoadjuvantchemotherapy
AT tanakayoshimichi urodynamicoutcomesafterpelvicnervesparingradicalhysterectomywithorwithoutneoadjuvantchemotherapy
AT tanakatomohito urodynamicoutcomesafterpelvicnervesparingradicalhysterectomywithorwithoutneoadjuvantchemotherapy
AT sasakihiroshi urodynamicoutcomesafterpelvicnervesparingradicalhysterectomywithorwithoutneoadjuvantchemotherapy
AT ibukinaokazu urodynamicoutcomesafterpelvicnervesparingradicalhysterectomywithorwithoutneoadjuvantchemotherapy
AT ubaitakanobu urodynamicoutcomesafterpelvicnervesparingradicalhysterectomywithorwithoutneoadjuvantchemotherapy
AT yamamotokazuhiro urodynamicoutcomesafterpelvicnervesparingradicalhysterectomywithorwithoutneoadjuvantchemotherapy
AT azumaharuhito urodynamicoutcomesafterpelvicnervesparingradicalhysterectomywithorwithoutneoadjuvantchemotherapy
AT ohmichimasahide urodynamicoutcomesafterpelvicnervesparingradicalhysterectomywithorwithoutneoadjuvantchemotherapy